MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Cerus Corporation ROE Ratio 2011-2026 | CERS
Annual ROE Ratio Cerus Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -24.33 | -37.26 | -70.15 | -62.39 | -63.51 | -57.66 | -124.88 | -68.11 | -155.59 | -108.86 | -58.95 | -93.34 | -101.27 | -83.3 | -92.73 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24.33 | -155.59 | -80.15 |
Quarterly ROE Ratio Cerus Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.64 | -41.09 | -50.11 | -51.02 | -71.3 | -86.04 | -78.18 | -74.81 | -60.05 | -37.66 | -53.0 | -56.89 | -64.19 | -52.42 | -66.04 | -64.32 | -60.41 | -43.81 | -73.47 | -91.34 | -107.8 | -124.88 | -114.39 | -99.69 | -84.62 | -68.11 | -78.43 | -96.1 | -124.25 | -155.59 | -149.45 | -139.87 | -127.44 | -108.86 | -101.07 | -92.73 | -78.15 | -58.95 | -91.99 | -101.36 | -102.78 | -93.34 | -58.42 | -80.42 | -77.85 | -101.27 | -96.55 | -66.76 | -61.03 | -83.3 | -116.56 | -86.11 | -111.13 | -92.73 | 12.34 | -35.0 | -27.84 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.34 | -155.59 | -80.5 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 21.65 | 1.12 % | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.9 | -0.18 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.3 | 1.55 % | $ 3.7 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.37 | 1.72 % | $ 151 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Heron Therapeutics
HRTX
|
-140.9 | - | - | $ 198 M | USA |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.25 | -1.26 % | $ 74.5 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
InflaRx N.V.
IFRX
|
-43.64 | $ 1.61 | 8.78 % | $ 152 M | Germany |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.4 | -0.71 % | $ 235 M | France |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Inventiva S.A.
IVA
|
-30.23 | $ 5.13 | -0.39 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
286.68 | $ 0.28 | -27.77 % | $ 653 K | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4039.99 | $ 19.16 | -2.39 % | $ 1.03 B | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | - | - | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.1 | 0.49 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.42 | 0.69 % | $ 2.98 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.42 | -1.39 % | $ 378 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.49 | $ 241.79 | 4.55 % | $ 4.42 B | USA |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
Eli Lilly and Company
LLY
|
77.78 | - | - | $ 783 B | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.92 | 0.34 % | $ 4.81 M | Israel |
 |
Esperion Therapeutics
ESPR
|
7.51 | - | - | $ 399 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |